Privia Health Group, Inc. () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1289751,
    "name": "Privia Health Group, Inc.",
    "stock_name": "Privia Health Group, Inc.",
    "full_name": "Privia Health Group, Inc.",
    "name_url": "stocks-analysis/privia-health-group-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "24.00",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "24.00",
    "mcapval": "2,895.20",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Insurance",
    "ind_code": 4865,
    "indexname": "S&P 500",
    "isin": "US74276R1023",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "753.91 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/privia-health-group-inc-1289751-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Privia Health Group, Inc. Experiences Revision in Its Stock Evaluation Amid Valuation Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/privia-health-groups-valuation-grade-changes-from-fair-to-very-expensive-3686373",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PriviaHealthGro_valuationdot_3686373.png",
        "date": "2025-11-10 16:27:50",
        "description": "Privia Health Group, Inc. has experienced a valuation adjustment, reflected in its high P/E ratio of 181 and elevated price-to-book value of 4.29. Despite a year-to-date return of 19.85%, the company has underperformed the S&P 500 over the past three years, highlighting competitive challenges in the insurance sector."
      },
      {
        "title": "Privia Health Group, Inc. Hits New 52-Week High of $26.51",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/privia-health-group-inc-hits-new-52-week-high-of-2651-3680208",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PriviaHealthGro_priceRelatedfactors_3680208.png",
        "date": "2025-11-07 16:13:45",
        "description": "Privia Health Group, Inc. achieved a new 52-week high of USD 26.51 on November 6, 2025, reflecting a 41.47% increase over the past year. With a market cap of USD 2,895 million, the company shows strong performance metrics, including a P/E ratio of 181.00 and a return on equity of 2.17%."
      },
      {
        "title": "Privia Health Group, Inc. Experiences Revision in Its Stock Evaluation Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/privia-health-groups-valuation-grade-upgraded-from-very-expensive-to-attractive-3667203",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/PriviaHealthGro_valuationdot_3667203.png",
        "date": "2025-11-03 16:14:07",
        "description": "Privia Health Group, Inc. has recently adjusted its valuation, showcasing a notably high P/E ratio of 181 compared to industry peers. Its financial metrics, including a price-to-book value of 4.29 and an EV to EBITDA ratio of 82.17, highlight significant differences within the insurance sector."
      },
      {
        "title": "Is Privia Health Group, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-privia-health-group-inc-overvalued-or-undervalued-3651109",
        "imagepath": "",
        "date": "2025-10-28 11:13:13",
        "description": "As of 24 October 2025, the valuation grade for Privia Health Group, Inc. moved from very expensive to fair. The company appears to be overvalued, particularly when considering its P/E ratio of 181, which is significantly higher than peers like Globe Life, Inc. at 11.82 and Primerica, Inc. at 12.59. Additionally, the EV to EBITDA ratio of 82.17 and the Price to Book Value of 4.29 further highlight the premium at which Privia is trading compared to its industry counterparts.\n\nIn terms of performance, Privia Health Group has shown strong returns, with a year-to-date return of 32.94%, significantly outperforming the S&P 500's 15.47%. However, over the three-year period, the company has underperformed with a return of -19.34% compared to the S&P 500's 78.85%. This mixed performance, alongside its high valuation ratios, suggests that while the stock may have short-term appeal, it is fundamentally overvalued in th..."
      },
      {
        "title": "Privia Health Group, Inc. Experiences Evaluation Revision Amidst Unique Market Positioning",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/privia-health-groups-valuation-grade-changes-from-very-expensive-to-fair-3649156",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/PriviaHealthGro_valuationdot_3649156.png",
        "date": "2025-10-27 16:16:13",
        "description": "Privia Health Group, Inc. has recently adjusted its valuation, showcasing a high P/E ratio of 181 compared to peers like Globe Life and Primerica. Despite a year-to-date return of 32.94%, Privia's three-year performance has declined by 19.34%, indicating contrasting trends within the insurance sector."
      },
      {
        "title": "Is Privia Health Group, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-privia-health-group-inc-overvalued-or-undervalued-3647615",
        "imagepath": "",
        "date": "2025-10-27 11:13:20",
        "description": "As of 24 October 2025, the valuation grade for Privia Health Group, Inc. moved from very expensive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 181, significantly higher than peers like Globe Life, Inc. with a P/E of 11.82 and Primerica, Inc. at 12.59, indicating a stark contrast in valuation. Additionally, the EV to EBITDA ratio is 82.17, which also suggests a premium compared to the industry.\n\nIn terms of performance, Privia Health has shown a strong return of 48.68% over the past year, compared to the S&P 500's 16.90%, highlighting its relative strength in the market despite its high valuation ratios. The company's ROCE of 11.11% and ROE of 2.37% further illustrate its operational efficiency, although these figures still reflect a need for improvement relative to its peers. Overall, while Privia Health Group, Inc. is currently fairly valued, its ..."
      },
      {
        "title": "Is Privia Health Group, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-privia-health-group-inc-overvalued-or-undervalued-3646154",
        "imagepath": "",
        "date": "2025-10-26 11:09:50",
        "description": "As of 24 October 2025, the valuation grade for Privia Health Group, Inc. has moved from very expensive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 181, which is significantly higher than peers like Globe Life, Inc. at 11.82 and Primerica, Inc. at 12.59. Additionally, the EV to EBITDA ratio is 82.17, compared to Equitable Holdings, Inc. at 9.97, indicating that Privia is trading at a premium relative to its peers.\n\nIn terms of performance, Privia Health Group has shown strong returns, with a year-to-date return of 32.94%, outperforming the S&P 500's 15.47% during the same period. However, over three years, it has underperformed the benchmark, with a return of -19.34% compared to the S&P 500's 78.85%. Overall, while Privia Health Group is currently fairly valued, its high valuation ratios suggest caution in the context of its performance relative to ..."
      },
      {
        "title": "Is Privia Health Group, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-privia-health-group-inc-overvalued-or-undervalued-3637994",
        "imagepath": "",
        "date": "2025-10-21 12:13:07",
        "description": "As of 17 October 2025, the valuation grade for Privia Health Group, Inc. moved from expensive to very expensive. This indicates that the company is overvalued, particularly when considering its high P/E ratio of 181, a price-to-book value of 4.29, and an EV to EBITDA of 82.17. In comparison to peers, Globe Life, Inc. has a fair P/E of 11.82, while Lincoln National Corp. boasts a very attractive P/E of 6.96, highlighting the significant premium at which Privia is trading.\n\nDespite its recent stock performance, where it outperformed the S&P 500 with a year-to-date return of 30.59% compared to the index's 13.30%, the valuation metrics suggest that the stock is not justified at its current price levels. The combination of high valuation ratios and the peer comparison strongly supports the conclusion that Privia Health Group, Inc. is overvalued...."
      },
      {
        "title": "Privia Health Group, Inc. Experiences Revision in Its Stock Evaluation Amid Premium Valuation Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/privia-health-groups-valuation-grade-upgraded-from-expensive-to-very-expensive-3641186",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/PriviaHealthGro_valuationdot_3641186.png",
        "date": "2025-10-20 17:39:07",
        "description": "Privia Health Group, Inc. has experienced a valuation adjustment, reflected in its high P/E ratio of 181 and elevated price-to-book value of 4.29. Despite strong recent returns, its three-year performance has declined significantly compared to the S&P 500, indicating a contrasting market position within the insurance sector."
      }
    ],
    "total": 22,
    "sid": "1289751",
    "stock_news_url": "https://www.marketsmojo.com/news/privia-health-group-inc-1289751"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Privia Health Group, Inc. Experiences Revision in Its Stock Evaluation Amid Valuation Metrics

2025-11-10 16:27:50

Privia Health Group, Inc. has experienced a valuation adjustment, reflected in its high P/E ratio of 181 and elevated price-to-book value of 4.29. Despite a year-to-date return of 19.85%, the company has underperformed the S&P 500 over the past three years, highlighting competitive challenges in the insurance sector.

Privia Health Group, Inc. Hits New 52-Week High of $26.51

2025-11-07 16:13:45

Privia Health Group, Inc. achieved a new 52-week high of USD 26.51 on November 6, 2025, reflecting a 41.47% increase over the past year. With a market cap of USD 2,895 million, the company shows strong performance metrics, including a P/E ratio of 181.00 and a return on equity of 2.17%.

Privia Health Group, Inc. Experiences Revision in Its Stock Evaluation Metrics

2025-11-03 16:14:07

Privia Health Group, Inc. has recently adjusted its valuation, showcasing a notably high P/E ratio of 181 compared to industry peers. Its financial metrics, including a price-to-book value of 4.29 and an EV to EBITDA ratio of 82.17, highlight significant differences within the insurance sector.

Is Privia Health Group, Inc. overvalued or undervalued?

2025-10-28 11:13:13

As of 24 October 2025, the valuation grade for Privia Health Group, Inc. moved from very expensive to fair. The company appears to be overvalued, particularly when considering its P/E ratio of 181, which is significantly higher than peers like Globe Life, Inc. at 11.82 and Primerica, Inc. at 12.59. Additionally, the EV to EBITDA ratio of 82.17 and the Price to Book Value of 4.29 further highlight the premium at which Privia is trading compared to its industry counterparts. In terms of performance, Privia Health Group has shown strong returns, with a year-to-date return of 32.94%, significantly outperforming the S&P 500's 15.47%. However, over the three-year period, the company has underperformed with a return of -19.34% compared to the S&P 500's 78.85%. This mixed performance, alongside its high valuation ratios, suggests that while the stock may have short-term appeal, it is fundamentally overvalued in th...

Privia Health Group, Inc. Experiences Evaluation Revision Amidst Unique Market Positioning

2025-10-27 16:16:13

Privia Health Group, Inc. has recently adjusted its valuation, showcasing a high P/E ratio of 181 compared to peers like Globe Life and Primerica. Despite a year-to-date return of 32.94%, Privia's three-year performance has declined by 19.34%, indicating contrasting trends within the insurance sector.

Is Privia Health Group, Inc. overvalued or undervalued?

2025-10-27 11:13:20

As of 24 October 2025, the valuation grade for Privia Health Group, Inc. moved from very expensive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 181, significantly higher than peers like Globe Life, Inc. with a P/E of 11.82 and Primerica, Inc. at 12.59, indicating a stark contrast in valuation. Additionally, the EV to EBITDA ratio is 82.17, which also suggests a premium compared to the industry. In terms of performance, Privia Health has shown a strong return of 48.68% over the past year, compared to the S&P 500's 16.90%, highlighting its relative strength in the market despite its high valuation ratios. The company's ROCE of 11.11% and ROE of 2.37% further illustrate its operational efficiency, although these figures still reflect a need for improvement relative to its peers. Overall, while Privia Health Group, Inc. is currently fairly valued, its ...

Is Privia Health Group, Inc. overvalued or undervalued?

2025-10-26 11:09:50

As of 24 October 2025, the valuation grade for Privia Health Group, Inc. has moved from very expensive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 181, which is significantly higher than peers like Globe Life, Inc. at 11.82 and Primerica, Inc. at 12.59. Additionally, the EV to EBITDA ratio is 82.17, compared to Equitable Holdings, Inc. at 9.97, indicating that Privia is trading at a premium relative to its peers. In terms of performance, Privia Health Group has shown strong returns, with a year-to-date return of 32.94%, outperforming the S&P 500's 15.47% during the same period. However, over three years, it has underperformed the benchmark, with a return of -19.34% compared to the S&P 500's 78.85%. Overall, while Privia Health Group is currently fairly valued, its high valuation ratios suggest caution in the context of its performance relative to ...

Is Privia Health Group, Inc. overvalued or undervalued?

2025-10-21 12:13:07

As of 17 October 2025, the valuation grade for Privia Health Group, Inc. moved from expensive to very expensive. This indicates that the company is overvalued, particularly when considering its high P/E ratio of 181, a price-to-book value of 4.29, and an EV to EBITDA of 82.17. In comparison to peers, Globe Life, Inc. has a fair P/E of 11.82, while Lincoln National Corp. boasts a very attractive P/E of 6.96, highlighting the significant premium at which Privia is trading. Despite its recent stock performance, where it outperformed the S&P 500 with a year-to-date return of 30.59% compared to the index's 13.30%, the valuation metrics suggest that the stock is not justified at its current price levels. The combination of high valuation ratios and the peer comparison strongly supports the conclusion that Privia Health Group, Inc. is overvalued....

Privia Health Group, Inc. Experiences Revision in Its Stock Evaluation Amid Premium Valuation Metrics

2025-10-20 17:39:07

Privia Health Group, Inc. has experienced a valuation adjustment, reflected in its high P/E ratio of 181 and elevated price-to-book value of 4.29. Despite strong recent returns, its three-year performance has declined significantly compared to the S&P 500, indicating a contrasting market position within the insurance sector.

View All News